The Anktiva FDA approval now reaches a second group of bladder cancer patients. On 14 October 2026 the US Food and Drug Administration expanded the label of Anktiva (nogapendekin alfa inbakicept-pmln), used together with BCG, to cover adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) who have high-grade papillary-only tumours. The drug was first approved in April 2024 for BCG-unresponsive disease with carcinoma in situ (CIS), with or without papillary tumours, so the new decision adds patients whose tumours are papillary only, without CIS.
The change matters because papillary tumours are the most common form of NMIBC. It also rests on an extrapolation from the earlier CIS data and on single-arm results, which is why the caveats below are worth reading.
Anktiva FDA approval: key takeaways
- What changed: the label now covers BCG-unresponsive NMIBC with papillary-only tumours, in addition to CIS with or without papillary tumours.
- Who makes it: ImmunityBio, which announced the expansion on 14 October 2026.
- Evidence: a single-arm trial, QUILT-3.032, with a 62% complete response rate in 77 patients with CIS.
- How it is given: directly into the bladder (intravesical), together with BCG, never by injection.
- Key warning: delaying cystectomy (bladder removal) can allow the cancer to become muscle-invasive or spread.
What the Anktiva FDA approval changes
Per the company’s announcement, the indication reads: adult patients with BCG-unresponsive non-muscle invasive bladder cancer. The ImmunityBio announced that the expansion adds papillary-only disease to the existing CIS indication. The earlier approval is documented in FDA’s April 2024 approval letter, which covered adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumours.
ImmunityBio chief executive Richard Adcock said the decision establishes Anktiva as the first FDA-approved therapy for both CIS and papillary-only disease in BCG-unresponsive NMIBC. That is the company’s claim, and we have not independently verified it. The company had previously noted that the US National Comprehensive Cancer Network added the papillary-only use to its guidelines in March 2026, at a time when the use was not FDA-approved; see the company’s NCCN guidelines update for that earlier step.
Evidence behind the Anktiva FDA approval
The expansion draws on QUILT-3.032, a single-arm, multicentre trial in which patients received Anktiva with BCG. In cohort A, which enrolled 77 patients with BCG-unresponsive CIS, 62% had a complete response (95% confidence interval 51% to 73%). Among those who responded, 58% kept the response for at least 12 months and 40% for at least 24 months, according to the company.
Reports on the FDA’s review say the agency judged that the CIS results could be extrapolated to high-grade papillary disease. A separate papillary-only cohort was part of the company’s submission. Reported disease-free survival there varies by data cut: one report gives 55.4% at 12 months and 48.3% at 24 months in 72 evaluable patients, while another, using a July 2024 cut-off, gives 58.2% and 52.1%. We have not seen the full label, so we treat these figures as reported rather than confirmed.
Because there was no control arm, the trial cannot show how Anktiva with BCG compares with BCG alone or with other options such as bladder removal.
Dosing and safety under the Anktiva FDA approval
As reported from the prescribing information, the dose is 400 micrograms into the bladder together with BCG once a week for six weeks, with a second induction course possible at month three if disease persists, followed by maintenance instillations for up to 37 months. We could not open the full label, so check it for exact instructions.
- Common reactions (15% or more of patients): increased creatinine, painful urination, blood in the urine, urinary frequency and urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and fever.
- Severity: the company says most treatment-related events were grade 1 to 2 and related to bladder instillation, consistent with BCG alone.
- Cystectomy warning: if high-grade disease persists after a second induction course, cystectomy should be reconsidered.
- Pregnancy: the drug may cause fetal harm, and people able to become pregnant should use effective contraception.
Why the Anktiva FDA approval matters for bladder cancer care
The US National Cancer Institute says about 70% to 80% of newly diagnosed bladder cancers are non-muscle-invasive (stages Ta, Tis or T1), and that intravesical BCG is the standard therapy for intermediate- and high-risk tumours. The company cites papillary disease as roughly 85% of NMIBC, a figure it attributes to published studies. For patients whose tumours stop responding to BCG, options have been limited, and cystectomy remains a major decision. A bladder-sparing choice for papillary disease therefore broadens what clinicians can discuss with patients, subject to the evidence limits above.
For related oncology and drug-development coverage, see our report on the Viking Therapeutics VK2735 Phase 3 trial and our other pharmaceutical news.
Risks and caveats of the Anktiva FDA approval
- No control arm: single-arm data cannot show superiority over BCG alone or surgery.
- Extrapolation: reports say the papillary-only decision leans on CIS results.
- Papillary data vary: reported disease-free survival differs by data cut.
- Delay risk: postponing cystectomy can allow progression, as the label warns.
- Company claims: statements such as being the first therapy for both indications are the company’s own.
In our assessment, the approval is best read as a regulatory widening that depends on the strength of the CIS evidence, not as new proof from a controlled trial. The practical question for urologists will be which patients with BCG-unresponsive papillary tumours are good candidates, and how long a trial of the combination is safe before cystectomy is reconsidered.
What to watch next after the Anktiva FDA approval
- Publication of the full prescribing information and any postmarketing requirements for the new indication.
- Longer follow-up from the papillary cohort.
- Progress on QUILT-3.032: the 2024 letter set trial completion for May 2029 and a final report for December 2029.
- Real-world data on bladder preservation and cystectomy rates.
- Coverage and access decisions by payers.
Frequently asked questions
What is the Anktiva FDA approval?
On 14 October 2026 the FDA expanded the use of Anktiva with BCG to adults with BCG-unresponsive NMIBC with high-grade papillary-only tumours, adding to its 2024 approval for CIS.
Who qualifies under the Anktiva FDA approval?
Adults whose non-muscle-invasive bladder cancer has stopped responding to BCG, with either CIS (with or without papillary tumours) or papillary-only high-grade disease. A doctor decides eligibility.
How is Anktiva given?
Directly into the bladder through a catheter, together with BCG. It is not given by injection or intravenously.
Does Anktiva replace cystectomy?
Not necessarily. The label warns that delaying cystectomy can be dangerous, and surgery should be reconsidered if high-grade disease persists after a second induction course.
Is Anktiva a cure?
No claim of cure has been made. The data show response rates and durations in a single-arm trial.
How we reported this: we relied on ImmunityBio’s announcement of 14 October 2026, the FDA’s April 2024 approval letter and reports on the new label, with background from the US National Cancer Institute. We could not open the full prescribing information. Last updated: 15 October 2026. This article is news reporting and not medical advice.